166 related articles for article (PubMed ID: 37986908)
1. Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and their Zebrafish Homologs at the Blood-Brain Barrier.
Inglut CT; Quinlan JA; Robey RW; Thomas JR; Walker JR; Zhou W; Huang HC; Gottesman MM
bioRxiv; 2023 Oct; ():. PubMed ID: 37986908
[TBL] [Abstract][Full Text] [Related]
2. Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier.
Thomas JR; Frye WJE; Robey RW; Warner AC; Butcher D; Matta JL; Morgan TC; Edmondson EF; Salazar PB; Ambudkar SV; Gottesman MM
bioRxiv; 2024 Jan; ():. PubMed ID: 37425689
[TBL] [Abstract][Full Text] [Related]
3. Abcg2a is the functional homolog of human ABCG2 expressed at the zebrafish blood-brain barrier.
Thomas JR; Frye WJE; Robey RW; Warner AC; Butcher D; Matta JL; Morgan TC; Edmondson EF; Salazar PB; Ambudkar SV; Gottesman MM
Fluids Barriers CNS; 2024 Mar; 21(1):27. PubMed ID: 38491505
[TBL] [Abstract][Full Text] [Related]
4. Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter.
Robey RW; Robinson AN; Ali-Rahmani F; Huff LM; Lusvarghi S; Vahedi S; Hotz JM; Warner AC; Butcher D; Matta J; Edmondson EF; Lee TD; Roth JS; Lee OW; Shen M; Tanner K; Hall MD; Ambudkar SV; Gottesman MM
Sci Rep; 2021 Dec; 11(1):24150. PubMed ID: 34921178
[TBL] [Abstract][Full Text] [Related]
5. ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an
Hotz JM; Thomas JR; Katz EN; Robey RW; Horibata S; Gottesman MM
Cancer Drug Resist; 2021; 4(3):620-633. PubMed ID: 34308273
[TBL] [Abstract][Full Text] [Related]
6. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
9. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
[TBL] [Abstract][Full Text] [Related]
10. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
11. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
12. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
Moreno-Sanz G; Barrera B; Armirotti A; Bertozzi SM; Scarpelli R; Bandiera T; Prieto JG; Duranti A; Tarzia G; Merino G; Piomelli D
Pharmacol Res; 2014 Sep; 87():87-93. PubMed ID: 24993496
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the ATP-binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood-brain barrier endothelial cells.
Ho YS; Torres-Vergara P; Penny J
Br J Pharmacol; 2023 Dec; 180(23):3092-3109. PubMed ID: 37476954
[TBL] [Abstract][Full Text] [Related]
15. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
16. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
17. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
18. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
[TBL] [Abstract][Full Text] [Related]
19. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
[TBL] [Abstract][Full Text] [Related]
20. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
